Targeted protein degraders: a call for collective action to advance safety assessment

被引：19

作者：

Jones, Lyn H. ^{[1
]}

Mitchell, Constance A. ^{[2
]}

Loberg, Lise ^{[3
]}

Pavkovic, Mira ^{[4
]}

Rao, Mohan ^{[5
]}

Roberts, Ruth ^{[6
,7
]}

Stamp, Katie ^{[8
]}

Volak, Laurie ^{[5
]}

Wittwer, Matthias B. ^{[9
]}

Pettit, Syril ^{[2
]}

机构：

[1] Dana Farber Canc Inst, Ctr Prot Degradat, Boston, MA 02115 USA

[2] Hlth & Environm Sci Inst, Washington, DC 17602 USA

[3] AbbVie, N Chicago, IL 60064 USA

[4] Bayer, Wuppertal, Germany

[5] Janssen Pharmaceut Companies Johnson & Johnson, San Diego, CA USA

[6] ApconiX, Alderley Edge, England

[7] Univ Birmingham, Dept Biosci, Birmingham, W Midlands, England

[8] Bristol Myers Squibb, New York, NY USA

[9] F Hoffmann La Roche, Roche Innovat Ctr Basel, Basel, Switzerland

来源：

NATURE REVIEWS DRUG DISCOVERY | 2022年 / 21卷 / 06期

关键词：

D O I：

10.1038/d41573-022-00055-9

中图分类号：

Q81 [生物工程学（生物技术）]; Q93 [微生物学];

学科分类号：

071005 ; 0836 ; 090102 ; 100705 ;

摘要：

Targeted protein degraders (TPDs) are emerging classes of therapeutics that have the potential to address difficult drug targets in new ways. In 2021, experts convened to discuss challenges in TPD safety evaluation, and supported supplementing individual efforts to address these challenges with collective development of novel decision frameworks, tools and a shared evidence base. Targeted protein degraders (TPDs) are emerging classes of therapeutics that have the potential to address difficult drug targets in new ways. In 2021, experts convened to discuss challenges in TPD safety evaluation, and supported supplementing individual efforts to address these challenges with collective development of novel decision frameworks, tools and a shared evidence base.

引用

页码：401 / 402

页数：2

共 50 条

[31] A call to action: the compelling need to advance the role of urgency [J].

David R. Staskin .

World Journal of Urology, 2009, 27 :765-766

[32] Design and optimization of targeted protein degraders: Leveraging computational tools [J].

Che, Ye .

ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2019, 258

[33] Recent advances in targeted protein degraders as potential therapeutic agents [J].

Yang, Na ;

Kong, Bo ;

Zhu, Zhaohong ;

Huang, Fei ;

Zhang, Liliang ;

Lu, Tao ;

Chen, Yadong ;

Zhang, Yanmin ;

Jiang, Yulei .

MOLECULAR DIVERSITY, 2024, 28 (01) :309-333

[34] Applications of contemporary tools to measure plasma protein binding of targeted protein degraders [J].

Niosi, Mark ;

Zhang, Sam ;

Burchett, Woodrow ;

Heck, Carley J. S. ;

Goetz, Gilles H. ;

Federico, James J. ;

Gernhardt, Steven ;

Jordan, Samantha ;

Gilbert, Adam M. ;

Calabrese, Matthew F. ;

Obach, R. Scott ;

Steyn, Stefanus J. .

DRUG METABOLISM AND DISPOSITION, 2025, 53 (05)

[35] Targeted degradation of MERTK and other TAM receptor paralogs by heterobifunctional targeted protein degraders [J].

Gadiyar, Varsha ;

Patel, Gopi ;

Chen, Jesse ;

Vigil, Dominico ;

Ji, Nan ;

Campbell, Veronica ;

Sharma, Kirti ;

Shi, Yatao ;

Weiss, Matthew M. ;

Birge, Raymond B. ;

Davra, Viralkumar .

FRONTIERS IN IMMUNOLOGY, 2023, 14

[36] Call for ''assessment in action'' manuscripts [J].

Hansen, JC .

MEASUREMENT AND EVALUATION IN COUNSELING AND DEVELOPMENT, 1996, 29 (01) :3-3

[37] Humanized CRBN knockin mice enable in vivo assessment the efficacy and toxicity of CRBN-targeted protein degraders [J].

Li, Yi ;

Qiu, Xiaolei ;

Feng, Liping ;

Feng, Dongxiao ;

Sun, Ruilin .

CANCER RESEARCH, 2025, 85 (08)

[38] Global call to action on MR safety [J].

Ordidge, R ;

Fullerton, GD .

JMRI-JOURNAL OF MAGNETIC RESONANCE IMAGING, 1999, 9 (05) :629-629

[39] Patient safety: A(nother) call for action [J].

DeMaria, AN .

JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2004, 44 (06) :1337-1338

[40] Patient safety in geriatrics: A call for action [J].

Tsilimingras, D ;

Rosen, AK ;

Berlowitz, DR .

JOURNALS OF GERONTOLOGY SERIES A-BIOLOGICAL SCIENCES AND MEDICAL SCIENCES, 2003, 58 (09) :813-819

← 1 2 3 4 5 →